The FDA approved efanesoctocog alfa, a once-weekly treatment for children and adults with hemophilia A.The approval applies to use of the factor VIII replacement therapy as routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment for control of bleeds, and for perioperative management of bleeding. Efanesoctocog alfa (Altuviiio; Bioverativ Therapeutics, Sanofi) is not